Home

Michael Wayne Kalb

CIK 1678248 · Chief Financial Officer · last filed 2026-07-17

Michael Wayne Kalb is a Chief Financial Officer who has filed 49 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing shows the insider disposed of $430.4K of CPRX on Jul 17, 2026. Across all open-market trades the lifetime net is −$10.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $194.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$194.0K

Companies

4

Total Filings

49

Lifetime Open-Market Net

-$10.41M

Filer Profile

Reported Address
24 LUCILLE LANE
DIX HILLS, NY 11746
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted Chief Financial Officer 0 $31.49 $0 $0 5 2026-07-17
IPI Legacy Liquidation Co (IMPL) Delisted CFO — $0.24 — $0 1 2023-05-12
CinCor Pharma, Inc. (CINC) Delisted EVP & Chief Financial Officer 0 $29.06 $0 $0 3 2023-02-24
AMRN SVP and CFO 14,233 $13.63 $194.0K -$10.41M 40 2022-08-02

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-17 CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted Disp (D) −13,665 -$430.4K EDGAR
2026-01-06 CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted Mixed +5,059 $0 EDGAR
2025-11-24 CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted Mixed +4,409 $0 EDGAR
2025-01-03 CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted Mixed +4,197 $0 EDGAR
2024-11-25 CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted Grant (A) — $0 EDGAR
2023-05-12 IPI Legacy Liquidation Co (IMPL) Delisted Grant (A) — $0 EDGAR
2023-02-24 CinCor Pharma, Inc. (CINC) Delisted Disp (D) −202,437 $0 EDGAR
2023-01-30 CinCor Pharma, Inc. (CINC) Delisted Grant (A) +177,000 $0 EDGAR
2022-11-08 CinCor Pharma, Inc. (CINC) Delisted Grant (A) +25,437 $0 EDGAR
2022-08-02 AMRN Mixed +865 -$62.4K EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.